title: [Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of modified FOLFIRI regimen in advanced colorectal cancer (CRC) patients refractory to fluoropyrimidine and oxaliplatin.
  
  
  METHODS
  The modified FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m2 d1 + LV 200 mg/m2 dl + 5-Fu 400 mg/m2 bolus dl plus 46-hour intravenous infusion of 5-Fu 2.4 g/m2, every 2 weeks as one cycle. The main selection criterion for this study was the advanced CRC refractory to fluoropyrimidine and oxaliplatin.
  
  
  RESULTS
  Of the 80 evaluable patients for efficacy: 10 (12.5%) had a partial response, 51 (63.7%) stable disease, and 19 (23.8%) progressive disease. The median time to progression was 96 days. Safety analysis was based on the data of 83 evaluable patients. The most frequently observed grade 3 or 4 toxicities were neutropenia (24.1%), nausea/vomiting (8.4%), and diarrhea (2.4%).
  
  
  CONCLUSIONS
  Modified FOLFIRI regimen is effective and well tolerated in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
authors: Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai 200032, China.
authors: Wen
authors: W
authors: Zhang
authors: Zi-Yi
authors: ZY
authors: Zhao
authors: Qing
authors: Q
authors: Wu
authors: Jia
authors: J
authors: Cheng
authors: Nong
authors: N
authors: Xu
authors: Chang-Ping
authors: CP
authors: Wu
authors: Jin
authors: J
authors: Li
authors: Li-Gong
authors: LG
authors: Xu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011743:Pyrimidines; D000077150:Oxaliplatin; C029269:5-fluoropyrimidine; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin